Professional Documents
Culture Documents
PALAKKAD
DR.K.A.NAZAR
DISTRICT SURVEILLANCE OFFICER &
DEPUTY DISTRICRT MEDICAL OFFICER ,
DMO(H), PALAKKIAD
LF: Global
GLOBAL SCENARIO
947 Million at risk
In 2000 More than 120 million people
infected
40 million disfigured and incapacitated
76 million mf carriers and 44 million
diseased cases
25 million men suffer from genital
disease
15 million people suffer from
lymphoedema or elephantiasis
1 million with occult filariasis (TPE) and
other manifestations
LF Distribution in India
Endemic
areas
Non-endemic
areas
Uncertain
areas
Indian scenario
Endemic in 250 districts of 16 states and 5 UTs
7 states Bihar, UP, AP, TN, Kerala, Orissa, WB
contribute to > 90% of the problem
Kerala
One of the 7 most endemic states
11 of the 14 districts are endemic
Both W.bancrofti and B.malayi are
endemic
B.malayi is on the decline and W.bancrofti
on the increase
History of MDA
Started in 2 districts in 1997- ALP& KKD
Extended to 9 more districts in 2004(Except PTA,
IDK & WND)
Both DEC and Alb. Tablets since 2008
Since 2013 MDA in 6 districts only.
2014 also MDA in 6 districts only.
{2014-15 TAS planned in 5 districts-KLM,
KTM,ALP,EKM,TSR (Successfully completed in all
except ALP)
2015 TAS planned in 4 districts (TVM, ALP,
KKD& KNR)}
2015 MDA in 3 districts only- PKD, MLP & KGD.
2016 TAS planned in 2 districts (MLP & KGD)}
2016 MDA IN PALAKKAD DISTRICT ONLY.
72.6 78.6
90.0
87.7
75.8
78.3
81.4
80.3
77.8
83.1
KLM
83.2 86.3
86.0
94.4
80.0
79.3
85.4
86.5
0.0
0.0
ALP
86.6 79.1
81.7
92.3
82.7
84.4
94.2
83.3
0.0
0.0
KTM
85.3 96.6
97.5
97.1
82.0
79.8
86.1
73.6
0.0
0.0
EKM
75.3 87.1
86.7
91.7
79.3
63.7
87.5
85.0
0.0
0.0
TSR
96.0 91.8
96.8
95.8
77.5
89.1
92.8
97.7
0.0
0.0
PKD
2015
86. 94.
70.
96.0 95.7
84.2 86.0 74.8 80.1 85.1 83.83
5
9
6
MLP
91.4 94.6
96.6
95.0
85.7
93.5
92.6
64.2
67.5
72
KKD
93.1 95.0
87.3
94.8
69.1
85.0
95.2
75.8
68.7
89.5
KNR
89.8 93.4
99.3
91.5
83.8
82.8
94.0
96.0
77.2
88.1
KGD
92.0 98.5
98.5
95.9
61.6
77.1
94.4
74.2
69.5
78.7
KERALA
86.5 90.5
92.4
93.8
77.1
81.6
90.0
81.0
73.5
82.3
MDA IN
PALAKKAD DISTRICT
MORBIDITY MANAGEMENT
DETAILS
2015
2016
899
940
TOTAL LYMPHOEDEMA
CASES MANAGED
(CUMULATIVE)
117
106
442
172
279
110
TOTAL HYDROCELE
CASES OPERATED
(CUMULATIVE)
60
51.76
Distribution %
CONSD
10
90
80
76.2
72
71.82
70
67.4
70.87
62.5
Distribution
%
60
50
42.16
41.6
42.64
42.13
40
31.35
30
27.2
20
12.6
10
0
3.5
28
Drug distribution and consumption in Rural and Urban areas of Palakkad district
80
72.66
69.65
70
60
50
42.66
42.63
40
30
20
10
0
Urban
Rural
Assessed
distribution
Consumption
80.1
70.87
60.16
42.64
SIDE EFFECTS
Lythargy/Weakness(4.7%)
Fever(0.9%)
Vomiting/Headache(0.3% each)
Nausea(0.2%)
Sedation/Body pain/Abd.pain(0.1%
each)
Itching(0.03%)
Others(8.7%)
STRATEGIES
NOV-11TH
1ST PHASE
TO 24ST IN HOT SPOTS/ HR
AREAS
2ND PHASE
NOV- 25TH TO DEC 8TH IN ALL OTHER
AREAS.
1.PALAKKAD MUNICIPALITY
2.MARUTHARODE
18.MALAMPUZHA
3.PUTHUSSERY
4.PIRAYIRI
5.PUTHUPARIYARAM
6.AKATHETHARA
7.KODUMBA
8.KODUVAYUR
9.KOLLENGODE
10.NEMMARA
11.KUNISSERY
12.ALTHUR
13.MATHUR
14.KOTTAYI
15.COYALMANNAM
16.THENKURISSY
17. PALLASSENA
19.KANNADI
Objectives
To assess the
Drug distribution coverage
Drug consumption
coverage
Adverse reactions
Reasons for noncompliance
Status of microfilaria &
vector infection and
infectivity
ASHA workers
Anganwadi workers
Health staff
Nursing students
JHI/JPHN Trainees
CONCLUSION
65 to 80% consumption for 4-6 years
is required for stoppage of
transmission
Adverse reactions are nil, however
fear of side reactions is the major
reason for non consumption. Not
necessary is the second major reason
for non consumption
Advance planning, intensive IEC
activities, co-ordinated efforts and
THANK YOU